The mechanism of drug resistance in OM tumors is unclear, but some studies have suggested that it might be associated with gene mutations (such as KRAS, NRAS, BRAF) (27, 28); however, the scale of this study was relatively small and the results need further verification. This evidence concerns the gene KRAS and ocular melanoma.